Multiple Myeloma:@0.747978:0.035749:0.914540:0.035749:0.914540:0.019993:0.747978:0.019993:0.017684:0.011699:0.003848:0.006523:0.003848:0.013123:0.003848:0.012508:0.005330:0.017684:0.010314:0.012508:0.003848:0.012604:0.018049:0.013143
TREATMENT APPROACHES:@0.983689:0.278245:0.983689:0.065272:0.955679:0.065272:0.955679:0.278245:0.000000:0.000000:0.000000:0.057096:-0.123230:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.375913
89:@0.955522:0.038184:0.976595:0.038184:0.976595:0.018587:0.955522:0.018587:0.010536:0.010536
HANDBOOK OF ONCOLOGY:@0.679047:0.970015:0.915156:0.970015:0.915156:0.956010:0.679047:0.956010:0.011682:0.012657:0.012657:0.012726:0.009818:0.014864:0.014864:0.010109:0.004738:0.014864:0.008296:0.004738:0.014864:0.012657:0.013906:0.014864:0.007902:0.014864:0.014915:0.010126
In patients with a high clinical suspicion :@0.084242:0.096166:0.480463:0.096166:0.480463:0.080410:0.084242:0.080410:0.004349:0.011738:0.009833:0.013123:0.013143:0.006523:0.003848:0.012508:0.011738:0.006523:0.007466:0.009833:0.015990:0.003848:0.006523:0.011738:0.009833:0.013143:0.009833:0.011738:0.003848:0.012950:0.011738:0.009833:0.012450:0.003848:0.003848:0.011738:0.003848:0.012450:0.013143:0.003848:0.009833:0.007466:0.011699:0.007466:0.013123:0.003848:0.012450:0.003848:0.012604:0.011738:0.005330
of MM but a normal SPEP, the serum-free :@0.084242:0.112980:0.480499:0.112980:0.480499:0.097224:0.084242:0.097224:0.012604:0.006042:0.007374:0.017684:0.017684:0.007376:0.013123:0.011699:0.006523:0.007378:0.013143:0.007379:0.011738:0.012604:0.006317:0.018049:0.013143:0.003848:0.007389:0.009583:0.011392:0.010314:0.009021:0.005330:0.007376:0.006523:0.011738:0.012508:0.007379:0.007466:0.012508:0.005792:0.011699:0.018049:0.006388:0.006042:0.005707:0.012508:0.012508:0.005330
light-chain (FLC) assay  should be per-:@0.084242:0.129794:0.475133:0.129794:0.475133:0.114038:0.084242:0.114038:0.003848:0.003848:0.012950:0.011738:0.006523:0.006388:0.012450:0.011738:0.013143:0.003848:0.011738:0.013816:0.007100:0.009333:0.008890:0.015644:0.007100:0.013816:0.013143:0.007466:0.007466:0.013143:0.010314:0.005330:0.008505:0.007466:0.011738:0.012604:0.011699:0.003848:0.013181:0.013816:0.013123:0.012508:0.013816:0.013123:0.012508:0.005792:0.006388
formed.  The  serum  FLC  test  detects  light :@0.084242:0.146608:0.480480:0.146608:0.480480:0.130852:0.084242:0.130852:0.006042:0.012604:0.006319:0.018049:0.012508:0.013181:0.005330:0.005330:0.003331:0.008197:0.011738:0.012508:0.005330:0.003327:0.007466:0.012508:0.005792:0.011699:0.018049:0.005330:0.003331:0.009333:0.008890:0.015644:0.005330:0.003331:0.006523:0.012508:0.007466:0.006523:0.005330:0.003333:0.013181:0.012508:0.006523:0.012508:0.012450:0.006523:0.007466:0.005330:0.003331:0.003848:0.003848:0.012950:0.011738:0.006523:0.005330
chains (kappa or lambda) and will show :@0.084242:0.163423:0.480472:0.163423:0.480472:0.147667:0.084242:0.147667:0.012450:0.011738:0.013143:0.003848:0.011738:0.007466:0.007966:0.007100:0.009660:0.013143:0.013123:0.013123:0.013143:0.007978:0.012604:0.005792:0.007966:0.003848:0.013143:0.018049:0.013123:0.013181:0.013143:0.007100:0.007986:0.013143:0.011738:0.013181:0.007966:0.015990:0.003848:0.003848:0.003848:0.007984:0.007466:0.011738:0.012604:0.015990:0.005330
abnormality in the ratio of kappa to lamb-:@0.084242:0.180237:0.475142:0.180237:0.475142:0.164481:0.084242:0.164481:0.013143:0.013123:0.011738:0.012604:0.006321:0.018049:0.013143:0.003848:0.003848:0.006523:0.010314:0.005080:0.003848:0.011738:0.005068:0.006523:0.011738:0.012508:0.005059:0.005792:0.013143:0.006523:0.003848:0.012604:0.005063:0.012604:0.006042:0.005063:0.009660:0.013143:0.013123:0.013123:0.013143:0.005070:0.006523:0.012604:0.005061:0.003848:0.013143:0.018049:0.013123:0.006388
da in 60% of MM patients who do not have :@0.084242:0.197051:0.480494:0.197051:0.480494:0.181295:0.084242:0.181295:0.013181:0.013143:0.004330:0.003848:0.011738:0.004318:0.010660:0.010660:0.014913:0.004330:0.012604:0.006042:0.004314:0.017684:0.017684:0.004314:0.013123:0.013143:0.006523:0.003848:0.012508:0.011738:0.006523:0.007466:0.004320:0.015990:0.011738:0.012604:0.004314:0.013181:0.012604:0.004314:0.011738:0.012604:0.006523:0.004308:0.011738:0.013143:0.010660:0.012508:0.005330
an M-protein on SPEP.  The SFL has obvi-:@0.084242:0.213865:0.475153:0.213900:0.475153:0.198144:0.084242:0.198110:0.013143:0.011738:0.007666:0.017684:0.006388:0.013123:0.005717:0.012604:0.006523:0.012508:0.003848:0.011738:0.007658:0.012604:0.011738:0.007660:0.009583:0.011392:0.010314:0.009639:0.005330:0.012430:0.007666:0.008197:0.011738:0.012508:0.007658:0.009583:0.009333:0.008890:0.007662:0.011738:0.013143:0.007466:0.007678:0.012604:0.013123:0.010660:0.003848:0.697571
15:@0.292835:0.208281:0.305265:0.208281:0.305265:0.199095:0.292835:0.199095:0.006215:0.006215
ated the need for the urine Bence-Jones :@0.084251:0.230714:0.480529:0.230714:0.480529:0.214958:0.084251:0.214958:0.013143:0.006523:0.012508:0.013181:0.007312:0.006523:0.011738:0.012508:0.007312:0.011738:0.012508:0.012508:0.013181:0.007312:0.006042:0.012604:0.005792:0.007312:0.006523:0.011738:0.012508:0.007312:0.011699:0.005792:0.003848:0.011738:0.012508:0.007312:0.011045:0.012508:0.011738:0.012450:0.012508:0.006388:0.009275:0.012604:0.011738:0.012508:0.007466:0.005330
protein in many patients.  There is a small :@0.084251:0.247529:0.480454:0.247538:0.480454:0.231782:0.084251:0.231773:0.013123:0.005715:0.012604:0.006523:0.012508:0.003848:0.011738:0.005984:0.003848:0.011738:0.005984:0.018049:0.013143:0.011738:0.010314:0.005984:0.013123:0.013143:0.006523:0.003848:0.012508:0.011738:0.006523:0.007466:0.005330:0.012425:0.005984:0.008197:0.011738:0.012508:0.005703:0.012508:0.005984:0.003848:0.007466:0.005984:0.013143:0.005984:0.007466:0.018049:0.013143:0.003848:0.003848:0.642282
16:@0.317287:0.241919:0.329716:0.241919:0.329716:0.232734:0.317287:0.232734:0.006215:0.006215
fraction of MM patients who do not have :@0.084246:0.264353:0.480485:0.264353:0.480485:0.248597:0.084246:0.248597:0.006042:0.005792:0.013143:0.012450:0.006523:0.003848:0.012604:0.011738:0.006408:0.012604:0.006042:0.006408:0.017684:0.017684:0.006408:0.013123:0.013143:0.006523:0.003848:0.012508:0.011738:0.006523:0.007466:0.006408:0.015990:0.011738:0.012604:0.006408:0.013181:0.012604:0.006408:0.011738:0.012604:0.006523:0.006408:0.011738:0.013143:0.010660:0.012508:0.005330
an M protein detectable by any of these :@0.084246:0.281167:0.480485:0.281167:0.480485:0.265411:0.084246:0.265411:0.013143:0.011738:0.006850:0.017684:0.006850:0.013123:0.005715:0.012604:0.006523:0.012508:0.003848:0.011738:0.006850:0.013181:0.012508:0.006523:0.012508:0.012450:0.006523:0.013143:0.013123:0.003848:0.012508:0.006850:0.013123:0.010314:0.006850:0.013143:0.011738:0.010314:0.006850:0.012604:0.006042:0.006850:0.006523:0.011738:0.012508:0.007466:0.012508:0.005330
methods (“non-secretors”).:@0.084246:0.297981:0.335630:0.297981:0.335630:0.282225:0.084246:0.282225:0.018049:0.012508:0.006523:0.011738:0.012604:0.013181:0.007466:0.005330:0.007100:0.009660:0.011738:0.012604:0.011738:0.006388:0.007466:0.012508:0.012450:0.005698:0.012508:0.006523:0.012604:0.005792:0.007466:0.009313:0.007100:0.005330
A  total protein  test has been aptly :@0.102430:0.314795:0.480503:0.314795:0.480503:0.299040:0.102430:0.299040:0.014239:0.005330:0.009265:0.006523:0.012604:0.006523:0.013143:0.003848:0.014605:0.013123:0.005715:0.012604:0.006523:0.012508:0.003848:0.011738:0.005330:0.009263:0.006523:0.012508:0.007466:0.006523:0.014605:0.011738:0.013143:0.007466:0.014605:0.013123:0.012508:0.012508:0.011738:0.014605:0.013143:0.013123:0.006523:0.003848:0.010314:0.005330
called “poor man’s SPEP” and in a poor-:@0.084246:0.331610:0.475163:0.331610:0.475163:0.315854:0.084246:0.315854:0.012450:0.013143:0.003848:0.003848:0.012508:0.013181:0.007389:0.009660:0.013123:0.012604:0.012604:0.005792:0.007378:0.018049:0.013143:0.011738:0.006754:0.007466:0.007389:0.009583:0.011392:0.010314:0.011392:0.009313:0.007389:0.013143:0.011738:0.013181:0.007389:0.003848:0.011738:0.007389:0.013143:0.007389:0.013123:0.012604:0.012604:0.005792:0.006388
resource setting is a useful initial screening :@0.084246:0.348424:0.480508:0.348424:0.480508:0.332668:0.084246:0.332668:0.005713:0.012508:0.007466:0.012604:0.011699:0.005651:0.012450:0.012508:0.005550:0.007466:0.012508:0.006523:0.006523:0.003848:0.011738:0.012950:0.005546:0.003848:0.007466:0.005561:0.013143:0.005561:0.011699:0.007466:0.012508:0.006042:0.011699:0.003848:0.005561:0.003848:0.011738:0.003848:0.006523:0.003848:0.013143:0.003848:0.005561:0.007466:0.012450:0.005715:0.012508:0.012508:0.011738:0.003848:0.011738:0.012950:0.005330
test when performed in the setting of clini-:@0.084246:0.365238:0.475172:0.365238:0.475172:0.349482:0.084246:0.349482:0.006523:0.012508:0.007466:0.006523:0.005176:0.015990:0.011738:0.012508:0.011738:0.005167:0.013123:0.012508:0.006708:0.006042:0.012604:0.006319:0.018049:0.012508:0.013181:0.005176:0.003848:0.011738:0.005176:0.006523:0.011738:0.012508:0.005165:0.007466:0.012508:0.006523:0.006523:0.003848:0.011738:0.012950:0.005176:0.012604:0.006042:0.005176:0.012450:0.003848:0.003848:0.011738:0.003848:0.006388
cal suspicion for MM (such as back pain :@0.084246:0.382053:0.480495:0.382053:0.480495:0.366297:0.084246:0.366297:0.012450:0.013143:0.003848:0.008024:0.007466:0.011699:0.007466:0.013123:0.003848:0.012450:0.003848:0.012604:0.011738:0.008024:0.006042:0.012604:0.005792:0.008007:0.017684:0.017684:0.008013:0.007100:0.007466:0.011699:0.012450:0.011738:0.008024:0.013143:0.007466:0.008024:0.013123:0.013143:0.012450:0.009660:0.008024:0.013123:0.013143:0.003848:0.011738:0.005330
or  a  normocytic  anaemia). However,  in :@0.084246:0.398867:0.480489:0.398867:0.480489:0.383111:0.084246:0.383111:0.012604:0.005792:0.005330:0.005138:0.013143:0.005330:0.005147:0.011738:0.012604:0.006317:0.018049:0.012604:0.012450:0.010314:0.006523:0.003848:0.012450:0.005330:0.005143:0.013143:0.011738:0.013143:0.012508:0.018049:0.003848:0.013143:0.007100:0.005330:0.010487:0.013143:0.012604:0.015990:0.012508:0.010660:0.012508:0.003768:0.005330:0.005330:0.005143:0.003848:0.011738:0.005330
patients with decreased albumin, early :@0.084246:0.415681:0.480462:0.415681:0.480462:0.399925:0.084246:0.399925:0.013123:0.013143:0.006523:0.003848:0.012508:0.011738:0.006523:0.007466:0.012219:0.015990:0.003848:0.006523:0.011738:0.012219:0.013181:0.012508:0.012450:0.005711:0.012508:0.013143:0.007466:0.012508:0.013181:0.012219:0.013143:0.003848:0.013123:0.011699:0.018049:0.003848:0.011738:0.005330:0.012219:0.012508:0.013143:0.005792:0.003848:0.010314:0.005330
disease or low/non-secretory disease, this :@0.084246:0.432495:0.480487:0.432495:0.480487:0.416739:0.084246:0.416739:0.013181:0.003848:0.007466:0.012508:0.013143:0.007466:0.012508:0.007054:0.012604:0.005792:0.007043:0.003848:0.012604:0.015990:0.008409:0.011738:0.012604:0.011738:0.006388:0.007466:0.012508:0.012450:0.005705:0.012508:0.006523:0.012604:0.005792:0.010314:0.007043:0.013181:0.003848:0.007466:0.012508:0.013143:0.007466:0.012508:0.005330:0.007043:0.006523:0.011738:0.003848:0.007466:0.005330
may result in a normal total protein level :@0.084246:0.449310:0.480479:0.449310:0.480479:0.433554:0.084246:0.433554:0.018049:0.013143:0.010314:0.007880:0.005713:0.012508:0.007466:0.011699:0.003848:0.006523:0.007876:0.003848:0.011738:0.007878:0.013143:0.007876:0.011738:0.012604:0.006317:0.018049:0.013143:0.003848:0.007889:0.006523:0.012604:0.006523:0.013143:0.003848:0.007874:0.013123:0.005713:0.012604:0.006523:0.012508:0.003848:0.011738:0.007868:0.003848:0.012508:0.010660:0.012508:0.003848:0.005330
and a falsely normal result. Thus, in any pa-:@0.084246:0.466124:0.475157:0.466124:0.475157:0.450368:0.084246:0.450368:0.013143:0.011738:0.013181:0.004483:0.013143:0.004483:0.006042:0.013143:0.003848:0.007466:0.012508:0.003848:0.010314:0.004495:0.011738:0.012604:0.006323:0.018049:0.013143:0.003848:0.004483:0.005713:0.012508:0.007466:0.011699:0.003848:0.006523:0.005330:0.004483:0.008197:0.011738:0.011699:0.007466:0.005330:0.004483:0.003848:0.011738:0.004483:0.013143:0.011738:0.010314:0.004483:0.013123:0.013143:0.006388
tient with a strong suspicion of myeloma, :@0.084246:0.482938:0.480483:0.482938:0.480483:0.467182:0.084246:0.467182:0.006523:0.003848:0.012508:0.011738:0.006523:0.007466:0.015990:0.003848:0.006523:0.011738:0.007466:0.013143:0.007466:0.007466:0.006523:0.005713:0.012604:0.011738:0.012950:0.007466:0.007466:0.011699:0.007466:0.013123:0.003848:0.012450:0.003848:0.012604:0.011738:0.007466:0.012604:0.006042:0.007466:0.018049:0.010314:0.012508:0.003848:0.012604:0.018049:0.013143:0.005330:0.005330
a full work-up and referral to a specialist :@0.084246:0.499752:0.480474:0.499752:0.480474:0.483997:0.084246:0.483997:0.013143:0.008168:0.006042:0.011699:0.003848:0.003848:0.008178:0.015990:0.012604:0.005792:0.009660:0.006388:0.011699:0.013123:0.008159:0.013143:0.011738:0.013181:0.008166:0.005713:0.012508:0.006042:0.012508:0.005792:0.005792:0.013143:0.003848:0.008159:0.006523:0.012604:0.008161:0.013143:0.008168:0.007466:0.013123:0.012508:0.012450:0.003848:0.013143:0.003848:0.003848:0.007466:0.006523:0.005330
centre is required.:@0.084246:0.516567:0.251277:0.516567:0.251277:0.500811:0.084246:0.500811:0.012450:0.012508:0.011738:0.006523:0.005705:0.012508:0.005330:0.003848:0.007466:0.005330:0.005711:0.012508:0.013123:0.011699:0.003848:0.005717:0.012508:0.013181:0.005330
n   :@0.084242:0.547165:0.107051:0.547165:0.107051:0.538725:0.084242:0.538725:0.009762:0.003566:0.005914:0.003566
Imaging:@0.103485:0.550284:0.180512:0.550284:0.180512:0.534528:0.103485:0.534528:0.004349:0.018049:0.013143:0.012950:0.003848:0.011738:0.012950
Imaging is an important part of the diag-:@0.084242:0.567098:0.475161:0.567098:0.475161:0.551342:0.084242:0.551342:0.004349:0.018049:0.013143:0.012950:0.003848:0.011738:0.012950:0.006985:0.003848:0.007466:0.006985:0.013143:0.011738:0.006985:0.003848:0.018049:0.013123:0.012604:0.005792:0.006523:0.013143:0.011738:0.006523:0.006972:0.013123:0.013143:0.005792:0.006523:0.006975:0.012604:0.006042:0.006973:0.006523:0.011738:0.012508:0.006972:0.013181:0.003848:0.013143:0.012950:0.006388
nosis of myeloma. Cross-sectional imaging :@0.084242:0.583913:0.480492:0.583913:0.480492:0.568157:0.084242:0.568157:0.011738:0.012604:0.007466:0.003848:0.007466:0.004849:0.012604:0.006042:0.004834:0.018049:0.010314:0.012508:0.003848:0.012604:0.018049:0.013143:0.005330:0.004838:0.015644:0.005713:0.012604:0.007466:0.007466:0.006388:0.007466:0.012508:0.012450:0.006523:0.003848:0.012604:0.011738:0.013143:0.003848:0.004849:0.003848:0.018049:0.013143:0.012950:0.003848:0.011738:0.012950:0.005330
(whole-body, low-dose CT without con-:@0.084242:0.600727:0.475152:0.600727:0.475152:0.584971:0.084242:0.584971:0.007100:0.015990:0.011738:0.012604:0.003848:0.012508:0.006388:0.013123:0.012604:0.013181:0.010314:0.005330:0.011411:0.003848:0.012604:0.015990:0.006388:0.013181:0.012604:0.007466:0.012508:0.011411:0.015644:0.008197:0.011411:0.015990:0.003848:0.006523:0.011738:0.012604:0.011699:0.006523:0.011411:0.012450:0.012604:0.011738:0.006388
trast,  PET/CT  or  MRI) is more  sensitive to :@0.084242:0.617541:0.480497:0.617541:0.480497:0.601785:0.084242:0.601785:0.006523:0.005792:0.013143:0.007466:0.006523:0.005330:0.005330:0.004507:0.011392:0.010314:0.008197:0.008409:0.015644:0.008197:0.005330:0.004505:0.012604:0.005792:0.005330:0.004510:0.017684:0.011680:0.004349:0.007100:0.009852:0.003848:0.007466:0.009852:0.018049:0.012604:0.005707:0.012508:0.005330:0.004512:0.007466:0.012508:0.011738:0.007466:0.003848:0.006523:0.003848:0.010660:0.012508:0.009852:0.006523:0.012604:0.005330
detect lytic lesions than XR, but due con-:@0.084242:0.634355:0.475160:0.634355:0.475160:0.618599:0.084242:0.618599:0.013181:0.012508:0.006523:0.012508:0.012450:0.006523:0.006704:0.003848:0.010314:0.006523:0.003848:0.012450:0.006716:0.003848:0.012508:0.007466:0.003848:0.012604:0.011738:0.007466:0.006716:0.006523:0.011738:0.013143:0.011738:0.006706:0.011719:0.011680:0.005330:0.006706:0.013123:0.011699:0.006523:0.006716:0.013181:0.011699:0.012508:0.006716:0.012450:0.012604:0.011738:0.006388
sideration needs to be given to cost and :@0.084242:0.651170:0.480497:0.651170:0.480497:0.635414:0.084242:0.635414:0.007466:0.003848:0.013181:0.012508:0.005792:0.013143:0.006523:0.003848:0.012604:0.011738:0.007168:0.011738:0.012508:0.012508:0.013181:0.007466:0.007168:0.006523:0.012604:0.007162:0.013123:0.012508:0.007177:0.012950:0.003848:0.010660:0.012508:0.011738:0.007177:0.006523:0.012604:0.007162:0.012450:0.012604:0.007466:0.006523:0.007166:0.013143:0.011738:0.013181:0.005330
exposure to radiation and drugs that may :@0.084242:0.667984:0.480478:0.667984:0.480478:0.652228:0.084242:0.652228:0.012508:0.009236:0.013123:0.012604:0.007466:0.011699:0.005711:0.012508:0.005753:0.006523:0.012604:0.005753:0.005792:0.013143:0.013181:0.003848:0.013143:0.006523:0.003848:0.012604:0.011738:0.005753:0.013143:0.011738:0.013181:0.005753:0.013181:0.005792:0.011699:0.012950:0.007466:0.005753:0.006523:0.011738:0.013143:0.006523:0.005753:0.018049:0.013143:0.010314:0.005330
be nephrotoxic (gadolinium and contrast). :@0.084242:0.684798:0.480490:0.684798:0.480490:0.669042:0.084242:0.669042:0.013123:0.012508:0.003618:0.011738:0.012508:0.013123:0.011738:0.005713:0.012604:0.006523:0.012604:0.009236:0.003848:0.012440:0.003618:0.007100:0.012950:0.013143:0.013181:0.012604:0.003848:0.003848:0.011738:0.003848:0.011699:0.018049:0.003618:0.013143:0.011738:0.013181:0.003618:0.012450:0.012604:0.011738:0.006523:0.005792:0.013143:0.007466:0.006523:0.007100:0.005330:0.005330
Patients  for  whom  cross-sectional  imag-:@0.084242:0.701612:0.475144:0.701612:0.475144:0.685857:0.084242:0.685857:0.011392:0.013143:0.006523:0.003848:0.012508:0.011738:0.006523:0.007466:0.005330:0.005757:0.006042:0.012604:0.005792:0.005330:0.005752:0.015990:0.011738:0.012604:0.018049:0.005330:0.005757:0.012450:0.005711:0.012604:0.007466:0.007466:0.006388:0.007466:0.012508:0.012450:0.006523:0.003848:0.012604:0.011738:0.013143:0.003848:0.005330:0.005763:0.003848:0.018049:0.013143:0.012950:0.006388
ining  should  be  performed  are  patients :@0.084242:0.718427:0.480478:0.718427:0.480478:0.702671:0.084242:0.702671:0.003848:0.011738:0.003848:0.011738:0.012950:0.005330:0.005338:0.007466:0.011738:0.012604:0.011699:0.003848:0.013181:0.005330:0.005338:0.013123:0.012508:0.005330:0.005338:0.013123:0.012508:0.006710:0.006042:0.012604:0.006317:0.018049:0.012508:0.013181:0.005330:0.005338:0.013143:0.005715:0.012508:0.005330:0.005334:0.013123:0.013143:0.006523:0.003848:0.012508:0.011738:0.006523:0.007466:0.005330
with SMM and solitary plasmacytoma in :@0.084242:0.735241:0.480455:0.735241:0.480455:0.719485:0.084242:0.719485:0.015990:0.003848:0.006523:0.011738:0.009756:0.009583:0.017684:0.017684:0.009756:0.013143:0.011738:0.013181:0.009756:0.007466:0.012604:0.003848:0.003848:0.006523:0.013143:0.005792:0.010314:0.009756:0.013123:0.003848:0.013143:0.007466:0.018061:0.013143:0.012450:0.010314:0.006523:0.012604:0.018049:0.013143:0.009756:0.003848:0.011738:0.005330
whom  lytic lesions would “up-stage” the :@0.084242:0.752055:0.480492:0.752055:0.480492:0.736299:0.084242:0.736299:0.015990:0.011738:0.012604:0.018049:0.005330:0.003704:0.003848:0.010314:0.006523:0.003848:0.012450:0.009044:0.003848:0.012508:0.007466:0.003848:0.012604:0.011738:0.007466:0.009044:0.015990:0.012604:0.011699:0.003848:0.013181:0.009044:0.009660:0.011699:0.013123:0.006388:0.007466:0.006523:0.013143:0.012950:0.012508:0.009313:0.009044:0.006523:0.011738:0.012508:0.005330
diagnosis to MM; and patients with MGUS :@0.084242:0.768870:0.480492:0.768870:0.480492:0.753114:0.084242:0.753114:0.013181:0.003848:0.013143:0.012950:0.011738:0.012604:0.007466:0.003848:0.007466:0.006196:0.006523:0.012604:0.006186:0.017684:0.017684:0.005330:0.006196:0.013143:0.011738:0.013181:0.006196:0.013123:0.013143:0.006523:0.003848:0.012508:0.011738:0.006523:0.007466:0.006196:0.015990:0.003848:0.006523:0.011738:0.006196:0.017684:0.016779:0.012604:0.009583:0.005330
and bone pain. Whole-body low-dose CT :@0.084242:0.785684:0.480501:0.785684:0.480501:0.769928:0.084242:0.769928:0.013143:0.011738:0.013181:0.006504:0.013123:0.012604:0.011738:0.012508:0.006494:0.013123:0.013143:0.003848:0.011738:0.005330:0.006494:0.018473:0.011738:0.012604:0.003848:0.012508:0.006388:0.013123:0.012604:0.013181:0.010314:0.006504:0.003848:0.012604:0.015990:0.006388:0.013181:0.012604:0.007466:0.012508:0.006504:0.015644:0.008197:0.005330
without contrast is  preferred for its  con-:@0.084242:0.802498:0.475165:0.802498:0.475165:0.786742:0.084242:0.786742:0.015990:0.003848:0.006523:0.011738:0.012604:0.011699:0.006523:0.010314:0.012450:0.012604:0.011738:0.006523:0.005792:0.013143:0.007466:0.006523:0.010314:0.003848:0.007466:0.005330:0.004995:0.013123:0.005715:0.012508:0.006042:0.012508:0.005792:0.005705:0.012508:0.013181:0.010314:0.006042:0.012604:0.005792:0.010314:0.003848:0.006523:0.007466:0.005330:0.004995:0.012450:0.012604:0.011738:0.006388
venience and lower cost.  An important :@0.084242:0.819312:0.480486:0.819391:0.480486:0.803635:0.084242:0.803556:0.010660:0.012508:0.011738:0.003848:0.012508:0.011738:0.012450:0.012508:0.008005:0.013143:0.011738:0.013181:0.008005:0.003848:0.012604:0.015990:0.012508:0.005792:0.008005:0.012450:0.012604:0.007466:0.006523:0.005330:0.012435:0.008005:0.014239:0.011738:0.008005:0.003848:0.018049:0.013123:0.012604:0.005792:0.006523:0.013143:0.011738:0.006523:-0.189535
17:@0.329391:0.813772:0.341821:0.813772:0.341821:0.804587:0.329391:0.804587:0.006215:0.006215
differential cause for lytic bone lesions and :@0.084247:0.836206:0.480507:0.836206:0.480507:0.820450:0.084247:0.820450:0.013181:0.003848:0.006102:0.006042:0.012508:0.005711:0.012508:0.011738:0.006523:0.003848:0.013143:0.003848:0.004291:0.012450:0.013143:0.011699:0.007466:0.012508:0.004291:0.006042:0.012604:0.005792:0.004276:0.003848:0.010314:0.006523:0.003848:0.012450:0.004291:0.013123:0.012604:0.011738:0.012508:0.004291:0.003848:0.012508:0.007466:0.003848:0.012604:0.011738:0.007466:0.004291:0.013143:0.011738:0.013181:0.005330
hypercalcaemia is metastatic carcinoma, :@0.084247:0.853020:0.480479:0.853020:0.480479:0.837264:0.084247:0.837264:0.011738:0.010314:0.013123:0.012508:0.005657:0.012450:0.013143:0.003848:0.012450:0.013143:0.012508:0.018049:0.003848:0.013143:0.005034:0.003848:0.007466:0.005022:0.018049:0.012508:0.006523:0.013143:0.007466:0.006523:0.013143:0.006523:0.003848:0.012450:0.005022:0.012450:0.013143:0.005657:0.012450:0.003848:0.011738:0.012604:0.018049:0.013143:0.005330:0.005330
and a subset of these patients may have :@0.084247:0.869834:0.480513:0.869834:0.480513:0.854078:0.084247:0.854078:0.013143:0.011738:0.013181:0.006735:0.013143:0.006735:0.007466:0.011699:0.013123:0.007466:0.012508:0.006523:0.006735:0.012604:0.006042:0.006735:0.006523:0.011738:0.012508:0.007466:0.012508:0.006723:0.013123:0.013143:0.006523:0.003848:0.012508:0.011738:0.006523:0.007466:0.006735:0.018049:0.013143:0.010314:0.006735:0.011738:0.013143:0.010660:0.012508:0.005330
an incidental MGUS. If the bone-marrow :@0.084247:0.886648:0.480492:0.886648:0.480492:0.870892:0.084247:0.870892:0.013143:0.011738:0.008486:0.003848:0.011738:0.012450:0.003848:0.013181:0.012508:0.011738:0.006523:0.013143:0.003848:0.008486:0.017684:0.016779:0.012604:0.009583:0.005330:0.008486:0.004349:0.006042:0.008486:0.006523:0.011738:0.012508:0.008486:0.013123:0.012604:0.011738:0.012508:0.006388:0.018049:0.013143:0.005792:0.005702:0.012604:0.015990:0.005330
examination is not in keeping with myelo-:@0.084247:0.903463:0.475166:0.903463:0.475166:0.887707:0.084247:0.887707:0.012508:0.009236:0.013143:0.018049:0.003848:0.011738:0.013143:0.006523:0.003848:0.012604:0.011738:0.006435:0.003848:0.007466:0.006446:0.011738:0.012604:0.006523:0.006429:0.003848:0.011738:0.006437:0.009660:0.012508:0.012508:0.013123:0.003848:0.011738:0.012950:0.006446:0.015990:0.003848:0.006523:0.011738:0.006437:0.018049:0.010314:0.012508:0.003848:0.012604:0.006388
ma, a useful investigation is a biopsy of the :@0.084247:0.919840:0.480455:0.919840:0.480455:0.904084:0.084247:0.904084:0.018049:0.013143:0.005330:0.004522:0.013143:0.004522:0.011699:0.007466:0.012508:0.006042:0.011699:0.003848:0.004522:0.003848:0.011738:0.010660:0.012508:0.007466:0.006523:0.003848:0.012950:0.013143:0.006523:0.003848:0.012604:0.011738:0.004522:0.003848:0.007466:0.004535:0.013143:0.004522:0.013123:0.003848:0.012604:0.013123:0.007466:0.010314:0.004535:0.012604:0.006042:0.004522:0.006523:0.011738:0.012508:0.005330
lytic bone lesion.:@0.084247:0.936218:0.239206:0.936218:0.239206:0.920462:0.084247:0.920462:0.003848:0.010314:0.006523:0.003848:0.012450:0.005330:0.013123:0.012604:0.011738:0.012508:0.005330:0.003848:0.012508:0.007466:0.003848:0.012604:0.011738:0.005330
PROGNOSIS:@0.523636:0.096077:0.658162:0.096077:0.658162:0.076481:0.523636:0.076481:0.013170:0.013641:0.019756:0.019756:0.017404:0.019756:0.012230:0.006585:0.012230
The  prognosis  of  myeloma depends on :@0.523636:0.114655:0.919893:0.114655:0.919893:0.098899:0.523636:0.098899:0.008197:0.011738:0.012508:0.005330:0.005815:0.013123:0.005715:0.012604:0.012950:0.011738:0.012604:0.007466:0.003848:0.007466:0.005330:0.005819:0.012604:0.006042:0.005330:0.005817:0.018049:0.010314:0.012508:0.003848:0.012604:0.018049:0.013143:0.011161:0.013181:0.012508:0.013123:0.012508:0.011738:0.013181:0.007466:0.011161:0.012604:0.011738:0.005330
patient factors (age, comorbidities), stag-:@0.523636:0.130940:0.914547:0.130940:0.914547:0.115184:0.523636:0.115184:0.013123:0.013143:0.006523:0.003848:0.012508:0.011738:0.006523:0.005927:0.006042:0.013143:0.012450:0.006523:0.012604:0.005792:0.007466:0.005927:0.007100:0.013143:0.012950:0.012508:0.005330:0.005927:0.012450:0.012604:0.018049:0.012604:0.005792:0.013112:0.003848:0.013181:0.003848:0.006523:0.003848:0.012508:0.007466:0.007100:0.005330:0.005940:0.007466:0.006523:0.013143:0.012950:0.006388
ing (B2-microglobulin and albumin are :@0.523636:0.147225:0.919858:0.147225:0.919858:0.131470:0.523636:0.131470:0.003848:0.011738:0.012950:0.013989:0.007100:0.011045:0.010660:0.006388:0.018049:0.003848:0.012450:0.005717:0.012604:0.012950:0.003848:0.012604:0.013123:0.011699:0.003848:0.003848:0.011738:0.013989:0.013143:0.011738:0.013181:0.013989:0.013143:0.003848:0.013123:0.011699:0.018049:0.003848:0.011738:0.013989:0.013143:0.005715:0.012508:0.005330
used as surrogate  markers  for  tumour :@0.523636:0.163511:0.919891:0.163511:0.919891:0.147755:0.523636:0.147755:0.011699:0.007466:0.012508:0.013181:0.014778:0.013143:0.007466:0.014778:0.007466:0.011699:0.005792:0.005711:0.012604:0.012950:0.013143:0.006523:0.012508:0.005330:0.009433:0.018049:0.013143:0.005792:0.009660:0.012508:0.005792:0.007466:0.005330:0.009438:0.006042:0.012604:0.005792:0.005330:0.009435:0.006523:0.011699:0.018049:0.012604:0.011699:0.005792:0.005330
burden which in myeloma corresponds :@0.523636:0.179796:0.919883:0.179796:0.919883:0.164040:0.523636:0.164040:0.013123:0.011699:0.005677:0.013181:0.012508:0.011738:0.012123:0.015990:0.011738:0.003848:0.012450:0.011738:0.012123:0.003848:0.011738:0.012123:0.018049:0.010314:0.012508:0.003848:0.012604:0.018049:0.013143:0.012123:0.012450:0.012604:0.005792:0.005703:0.012508:0.007466:0.013123:0.012604:0.011738:0.013181:0.007466:0.005330
to staging), disease biology (cytogenetic :@0.523636:0.196081:0.919872:0.196081:0.919872:0.180325:0.523636:0.180325:0.006523:0.012604:0.007447:0.007466:0.006523:0.013143:0.012950:0.003848:0.011738:0.012950:0.007100:0.005330:0.007447:0.013181:0.003848:0.007466:0.012508:0.013143:0.007466:0.012508:0.007455:0.013123:0.003848:0.012604:0.003848:0.012604:0.012950:0.010314:0.007455:0.007100:0.012450:0.010314:0.006523:0.012604:0.012950:0.012508:0.011738:0.012508:0.006523:0.003848:0.012450:0.005330
abnormalities) and the response to initial :@0.523636:0.212366:0.919864:0.212366:0.919864:0.196610:0.523636:0.196610:0.013143:0.013123:0.011738:0.012604:0.006321:0.018049:0.013143:0.003848:0.003848:0.006523:0.003848:0.012508:0.007466:0.007100:0.007966:0.013143:0.011738:0.013181:0.007947:0.006523:0.011738:0.012508:0.007947:0.005713:0.012508:0.007466:0.013123:0.012604:0.011738:0.007466:0.012508:0.007947:0.006523:0.012604:0.007947:0.003848:0.011738:0.003848:0.006523:0.003848:0.013143:0.003848:0.005330
treatment. The revised International Stag-:@0.523636:0.228651:0.914547:0.228651:0.914547:0.212895:0.523636:0.212895:0.006523:0.005709:0.012508:0.013143:0.006523:0.018049:0.012508:0.011738:0.006523:0.005330:0.006889:0.008197:0.011738:0.012498:0.006889:0.005711:0.012508:0.010660:0.003848:0.007466:0.012508:0.013181:0.006902:0.004349:0.011738:0.006523:0.012508:0.006185:0.011738:0.013143:0.006523:0.003848:0.012604:0.011738:0.013143:0.003848:0.006889:0.009583:0.006523:0.013143:0.012950:0.006388
ing Score (R-ISS) is the  most  widely used :@0.523636:0.244936:0.919883:0.244936:0.919883:0.229180:0.523636:0.229180:0.003848:0.011738:0.012950:0.008928:0.009583:0.012450:0.012604:0.005707:0.012508:0.008928:0.007100:0.011680:0.006388:0.004349:0.009583:0.009583:0.007100:0.008928:0.003848:0.007466:0.008928:0.006523:0.011738:0.012508:0.005330:0.003585:0.018049:0.012604:0.007466:0.006523:0.005330:0.003589:0.015990:0.003848:0.013181:0.012508:0.003848:0.010314:0.008928:0.011699:0.007466:0.012508:0.013181:0.005330
staging system and combines measures :@0.523636:0.261221:0.919875:0.261221:0.919875:0.245465:0.523636:0.245465:0.007466:0.006523:0.013143:0.012950:0.003848:0.011738:0.012950:0.010391:0.007466:0.010314:0.007466:0.006523:0.012508:0.018049:0.010391:0.013143:0.011738:0.013181:0.010391:0.012450:0.012604:0.018049:0.013123:0.003848:0.011738:0.012508:0.007466:0.010391:0.018049:0.012508:0.013143:0.007466:0.011699:0.005715:0.012508:0.007466:0.005330
of tumour burden with disease biology to :@0.523636:0.277506:0.919889:0.277506:0.919889:0.261750:0.523636:0.261750:0.012604:0.006042:0.006889:0.006523:0.011699:0.018049:0.012604:0.011699:0.005792:0.006889:0.013123:0.011699:0.005677:0.013181:0.012508:0.011738:0.006889:0.015990:0.003848:0.006523:0.011738:0.006889:0.013181:0.003848:0.007466:0.012508:0.013143:0.007480:0.012508:0.006889:0.013123:0.003848:0.012604:0.003848:0.012604:0.012950:0.010314:0.006889:0.006523:0.012604:0.005330
identify three stages with variable overall :@0.523636:0.293791:0.919872:0.293791:0.919872:0.278035:0.523636:0.278035:0.003848:0.013181:0.012508:0.011738:0.006523:0.003848:0.006042:0.010314:0.007466:0.006523:0.011738:0.005707:0.012508:0.012508:0.007453:0.007466:0.006523:0.013143:0.012950:0.012508:0.007466:0.007455:0.015990:0.003848:0.006523:0.011738:0.007456:0.010660:0.013143:0.005792:0.003848:0.013143:0.013123:0.003848:0.012508:0.007466:0.012604:0.010660:0.012508:0.005792:0.013143:0.003848:0.003848:0.005330
survival rates (see Table 2).:@0.523636:0.310077:0.770002:0.310077:0.770002:0.294321:0.523636:0.294321:0.007466:0.011699:0.005792:0.010660:0.003848:0.010660:0.013143:0.003848:0.005330:0.005792:0.013143:0.006523:0.012508:0.007466:0.005330:0.007100:0.007466:0.012508:0.012508:0.005330:0.007202:0.013143:0.013123:0.003848:0.012508:0.005330:0.010660:0.007100:0.005330
18:@0.770010:0.304454:0.782440:0.304454:0.782440:0.295268:0.770010:0.295268:0.006215:0.006215
TREATMENT AND REFERRAL :@0.523636:0.343289:0.822791:0.343289:0.822791:0.323692:0.523636:0.323692:0.009878:0.013641:0.012230:0.017404:0.009878:0.021167:0.012230:0.017404:0.009878:0.006585:0.017404:0.017404:0.016463:0.006585:0.013641:0.012230:0.011289:0.012230:0.013641:0.013641:0.017404:0.010348:0.006585
GUIDELINES:@0.523636:0.362514:0.652517:0.362514:0.652517:0.342917:0.523636:0.342917:0.019756:0.015052:0.006585:0.016463:0.012230:0.010348:0.006585:0.017404:0.012230:0.012230
GENERAL MANAGEMENT:@0.523636:0.381415:0.774215:0.381415:0.774215:0.363600:0.523636:0.363600:0.017960:0.011118:0.015822:0.011118:0.012401:0.015822:0.009407:0.005987:0.019242:0.015822:0.015822:0.015822:0.017960:0.011118:0.019242:0.011118:0.015822:0.008980
Patients  with  MM  should be referred  for :@0.523636:0.398846:0.919899:0.398846:0.919899:0.383090:0.523636:0.383090:0.011392:0.013143:0.006523:0.003848:0.012508:0.011738:0.006523:0.007466:0.005330:0.004626:0.015990:0.003848:0.006523:0.011738:0.005330:0.004628:0.017684:0.017684:0.005330:0.004628:0.007466:0.011738:0.012604:0.011699:0.003848:0.013181:0.009968:0.013123:0.012508:0.009968:0.005713:0.012508:0.006042:0.012508:0.005792:0.005703:0.012508:0.013181:0.005330:0.004628:0.006042:0.012604:0.005792:0.005330
management to an oncologist or haema-:@0.523636:0.415131:0.914547:0.415131:0.914547:0.399375:0.523636:0.399375:0.018049:0.013143:0.011738:0.013143:0.012950:0.012508:0.018049:0.012508:0.011738:0.006523:0.005307:0.006523:0.012604:0.005313:0.013143:0.011738:0.005319:0.012604:0.011738:0.012450:0.012604:0.003848:0.012604:0.012950:0.003848:0.007466:0.006523:0.005307:0.012604:0.005792:0.005311:0.011738:0.013143:0.012508:0.018049:0.013143:0.006388
tologist. However, the role of the general :@0.523636:0.431416:0.919889:0.431416:0.919889:0.415660:0.523636:0.415660:0.006523:0.012604:0.003848:0.012604:0.012950:0.003848:0.007466:0.006523:0.005330:0.007562:0.013143:0.012604:0.015990:0.012508:0.010660:0.012508:0.003768:0.005330:0.007562:0.006523:0.011738:0.012508:0.007562:0.005713:0.012604:0.003848:0.012508:0.007562:0.012604:0.006042:0.007562:0.006523:0.011738:0.012508:0.007562:0.012950:0.012508:0.011738:0.012508:0.005792:0.013143:0.003848:0.005330
practitioner to diagnose, stabilise and ap-:@0.523636:0.447701:0.914538:0.447701:0.914538:0.431945:0.523636:0.431945:0.013123:0.005792:0.013143:0.012450:0.006523:0.003848:0.006523:0.003848:0.012604:0.011738:0.012508:0.005792:0.005715:0.006523:0.012604:0.005719:0.013181:0.003848:0.013143:0.012950:0.011738:0.012604:0.007466:0.012508:0.005330:0.005723:0.007466:0.006523:0.013143:0.013123:0.003848:0.003848:0.003848:0.007466:0.012508:0.005734:0.013143:0.011738:0.013181:0.005734:0.013143:0.013123:0.006388
propriately manage the complications of :@0.523636:0.463987:0.919885:0.463987:0.919885:0.448231:0.523636:0.448231:0.013123:0.005715:0.012604:0.013123:0.005792:0.003848:0.013143:0.006523:0.012508:0.003848:0.010314:0.006935:0.018049:0.013143:0.011738:0.013143:0.012950:0.012508:0.006929:0.006523:0.011738:0.012508:0.006927:0.012450:0.012604:0.018049:0.013123:0.003848:0.003848:0.012450:0.013143:0.006523:0.003848:0.012604:0.011738:0.007466:0.006947:0.012604:0.006042:0.005330
myeloma is of critical importance. Patients :@0.523636:0.480272:0.919883:0.480272:0.919883:0.464516:0.523636:0.464516:0.018049:0.010314:0.012508:0.003848:0.012604:0.018049:0.013143:0.004464:0.003848:0.007466:0.004464:0.012604:0.006042:0.004451:0.012450:0.005792:0.003848:0.006523:0.003848:0.012450:0.013143:0.003848:0.004464:0.003848:0.018049:0.013123:0.012604:0.005792:0.006523:0.013143:0.011738:0.012450:0.012508:0.005330:0.004447:0.011392:0.013143:0.006523:0.003848:0.012508:0.011738:0.006523:0.007466:0.005330
with  myeloma  may be  frail and  appear :@0.523636:0.496557:0.919881:0.496557:0.919881:0.480801:0.523636:0.480801:0.015990:0.003848:0.006523:0.011738:0.005330:0.003931:0.018049:0.010314:0.012508:0.003848:0.012604:0.018049:0.013143:0.005330:0.003931:0.018049:0.013143:0.010314:0.009275:0.013123:0.012508:0.005330:0.003933:0.006042:0.005792:0.013143:0.003848:0.003848:0.009275:0.013143:0.011738:0.013181:0.005330:0.003931:0.013143:0.013123:0.013123:0.012508:0.013143:0.005792:0.005330
terminally unwell at diagnosis (often with :@0.523636:0.512842:0.919866:0.512842:0.919866:0.497086:0.523636:0.497086:0.006523:0.012508:0.006319:0.018049:0.003848:0.011738:0.013143:0.003848:0.003848:0.010314:0.008132:0.011699:0.011738:0.015990:0.012508:0.003848:0.003848:0.008120:0.013143:0.006523:0.008120:0.013181:0.003848:0.013143:0.012950:0.011738:0.012604:0.007466:0.003848:0.007466:0.008120:0.007100:0.012604:0.006042:0.006523:0.012508:0.011738:0.008111:0.015990:0.003848:0.006523:0.011738:0.005330
a history of deterioration and decreased :@0.523636:0.529127:0.919889:0.529127:0.919889:0.513371:0.523636:0.513371:0.013143:0.007909:0.011738:0.003848:0.007466:0.006523:0.012604:0.005792:0.010314:0.007909:0.012604:0.006042:0.007909:0.013181:0.012508:0.006523:0.012508:0.005792:0.003848:0.012604:0.005792:0.013143:0.006523:0.003848:0.012604:0.011738:0.007887:0.013143:0.011738:0.013181:0.007909:0.013181:0.012508:0.012450:0.005711:0.012508:0.013143:0.007466:0.012508:0.013181:0.005330
mobility over months) and yet, despite the :@0.523636:0.545412:0.919895:0.545412:0.919895:0.529656:0.523636:0.529656:0.018049:0.012604:0.013123:0.003848:0.003848:0.003848:0.006523:0.010314:0.004888:0.012604:0.010660:0.012508:0.005792:0.004888:0.018049:0.012604:0.011738:0.006523:0.011738:0.007466:0.007100:0.004888:0.013143:0.011738:0.013181:0.004888:0.010314:0.012508:0.006523:0.005330:0.004888:0.013181:0.012508:0.007466:0.013123:0.003848:0.006523:0.012508:0.004888:0.006523:0.011738:0.012508:0.005330
incurable nature of the disease, many of :@0.523636:0.561697:0.919868:0.561697:0.919868:0.545941:0.523636:0.545941:0.003848:0.011738:0.012450:0.011699:0.005792:0.013143:0.013123:0.003848:0.012508:0.007447:0.011738:0.013143:0.006523:0.011699:0.005707:0.012508:0.007447:0.012604:0.006042:0.007447:0.006523:0.011738:0.012508:0.007447:0.013181:0.003848:0.007466:0.012508:0.013143:0.007466:0.012508:0.005330:0.007447:0.018049:0.013143:0.011738:0.010314:0.007447:0.012604:0.006042:0.005330
them can have a good quality of life for :@0.523636:0.577982:0.919895:0.577982:0.919895:0.562226:0.523636:0.562226:0.006523:0.011738:0.012508:0.018049:0.007545:0.012450:0.013143:0.011738:0.007551:0.011738:0.013143:0.010660:0.012508:0.007551:0.013143:0.007562:0.012950:0.012604:0.012604:0.013181:0.007541:0.013123:0.011699:0.013143:0.003848:0.003848:0.006523:0.010314:0.007562:0.012604:0.006042:0.007547:0.003848:0.003848:0.006042:0.012508:0.007562:0.006042:0.012604:0.005792:0.005330
years following diagnosis with therapy.:@0.523636:0.594267:0.880467:0.594267:0.880467:0.578511:0.523636:0.578511:0.010314:0.012508:0.013143:0.005792:0.007466:0.005330:0.006042:0.012604:0.003848:0.003848:0.012604:0.015990:0.003848:0.011738:0.012950:0.005330:0.013181:0.003848:0.013143:0.012950:0.011738:0.012604:0.007466:0.003848:0.007466:0.005330:0.015990:0.003848:0.006523:0.011738:0.005330:0.006523:0.011738:0.012508:0.005792:0.013143:0.013123:0.010314:0.005330
MGUS does not  require treatment.  The :@0.523636:0.610552:0.919899:0.610552:0.919899:0.594797:0.523636:0.594797:0.017684:0.016779:0.012604:0.009583:0.012315:0.013181:0.012604:0.012508:0.007466:0.012315:0.011738:0.012604:0.006523:0.005330:0.006972:0.005713:0.012508:0.013123:0.011699:0.003848:0.005715:0.012508:0.012315:0.006523:0.005711:0.012508:0.013143:0.006523:0.018049:0.012508:0.011738:0.006523:0.005330:0.005330:0.006970:0.008197:0.011738:0.012508:0.005330
follow-up of MGUS can be performed by :@0.523636:0.626838:0.919875:0.626838:0.919875:0.611082:0.523636:0.611082:0.006042:0.012604:0.003848:0.003848:0.012604:0.015990:0.006388:0.011699:0.013123:0.007004:0.012604:0.006042:0.007004:0.017684:0.016779:0.012604:0.009583:0.007004:0.012450:0.013143:0.011738:0.007004:0.013123:0.012508:0.007004:0.013123:0.012508:0.006708:0.006042:0.012604:0.006319:0.018049:0.012508:0.013181:0.007004:0.013123:0.010314:0.005330
a general practitioner. Current  recom-:@0.523636:0.643123:0.914568:0.643123:0.914568:0.627367:0.523636:0.627367:0.013143:0.014047:0.012950:0.012508:0.011738:0.012508:0.005792:0.013143:0.003848:0.014047:0.013123:0.005792:0.013143:0.012450:0.006523:0.003848:0.006523:0.003848:0.012604:0.011738:0.012508:0.004372:0.005330:0.014047:0.015644:0.011699:0.005792:0.005707:0.012508:0.011738:0.006523:0.005330:0.008707:0.005713:0.012508:0.012450:0.012604:0.018049:0.006388
mendations  are  to  repeat  a SPEP  in six :@0.523636:0.659408:0.919881:0.659408:0.919881:0.643652:0.523636:0.643652:0.018049:0.012508:0.011738:0.013181:0.013143:0.006523:0.003848:0.012604:0.011738:0.007466:0.005330:0.005259:0.013143:0.005715:0.012508:0.005330:0.005261:0.006523:0.012604:0.005330:0.005257:0.005711:0.012508:0.013123:0.012508:0.013143:0.006523:0.005330:0.005261:0.013143:0.010603:0.009583:0.011392:0.010314:0.011392:0.005330:0.005257:0.003848:0.011738:0.010603:0.007466:0.003848:0.009236:0.005330
months in all patients with MGUS and then :@0.523636:0.675693:0.919899:0.675693:0.919899:0.659937:0.523636:0.659937:0.018049:0.012604:0.011738:0.006523:0.011738:0.007466:0.005161:0.003848:0.011738:0.005176:0.013143:0.003848:0.003848:0.005176:0.013123:0.013143:0.006523:0.003848:0.012508:0.011738:0.006523:0.007466:0.005167:0.015990:0.003848:0.006523:0.011738:0.005176:0.017684:0.016779:0.012604:0.009583:0.005167:0.013143:0.011738:0.013181:0.005176:0.006523:0.011738:0.012508:0.011738:0.005330
further  follow-up, depending on the risk :@0.523636:0.691978:0.919895:0.691978:0.919895:0.676222:0.523636:0.676222:0.006042:0.011699:0.005792:0.006523:0.011738:0.012508:0.005792:0.005330:0.005195:0.006042:0.012604:0.003848:0.003848:0.012604:0.015990:0.006388:0.011699:0.013123:0.005330:0.010545:0.013181:0.012508:0.013123:0.012508:0.011738:0.013181:0.003848:0.011738:0.012950:0.010545:0.012604:0.011738:0.010545:0.006523:0.011738:0.012508:0.010545:0.005792:0.003848:0.007466:0.009660:0.005330
of the progression of MGUS: patients with :@0.523636:0.708263:0.919868:0.708263:0.919868:0.692507:0.523636:0.692507:0.012604:0.006042:0.007025:0.006523:0.011738:0.012508:0.007025:0.013123:0.005715:0.012604:0.012950:0.005705:0.012508:0.007466:0.007466:0.003848:0.012604:0.011738:0.007027:0.012604:0.006042:0.007025:0.017684:0.016779:0.012604:0.009583:0.005330:0.007027:0.013123:0.013143:0.006523:0.003848:0.012508:0.011738:0.006523:0.007466:0.007031:0.015990:0.003848:0.006523:0.011738:0.005330
low-risk MGUS (an M-protein of <1.5g/dL, :@0.523636:0.724548:0.919891:0.724548:0.919891:0.708792:0.523636:0.708792:0.003848:0.012604:0.015990:0.006388:0.005792:0.003848:0.007466:0.009660:0.008178:0.017684:0.016779:0.012604:0.009583:0.008166:0.007100:0.013143:0.011738:0.008178:0.017684:0.006388:0.013123:0.005715:0.012604:0.006523:0.012508:0.003848:0.011738:0.008161:0.012604:0.006042:0.008165:0.011661:0.010660:0.005330:0.010660:0.012950:0.008409:0.013181:0.008890:0.005330:0.005330
IgG subtype and normal FLC ratio) may :@0.523636:0.740833:0.919862:0.740833:0.919862:0.725077:0.523636:0.725077:0.004349:0.012950:0.016779:0.008986:0.007466:0.011699:0.013123:0.006523:0.010314:0.013123:0.012508:0.008986:0.013143:0.011738:0.013181:0.008986:0.011738:0.012604:0.006317:0.018049:0.013143:0.003848:0.008986:0.009333:0.008890:0.015644:0.008986:0.005792:0.013143:0.006523:0.003848:0.012604:0.007100:0.008986:0.018049:0.013143:0.010314:0.005330
be followed up with history and examina-:@0.523636:0.757118:0.914543:0.757118:0.914543:0.741362:0.523636:0.741362:0.013123:0.012508:0.006223:0.006042:0.012604:0.003848:0.003848:0.012604:0.015990:0.012508:0.013181:0.006221:0.011699:0.013123:0.006221:0.015990:0.003848:0.006523:0.011738:0.006221:0.011738:0.003848:0.007466:0.006523:0.012604:0.005792:0.010314:0.006219:0.013143:0.011738:0.013181:0.006223:0.012508:0.009236:0.013143:0.018049:0.003848:0.011738:0.013143:0.006388
tion alone.  All other patients with MGUS :@0.523636:0.773403:0.919860:0.773396:0.919860:0.757640:0.523636:0.757648:0.006523:0.003848:0.012604:0.011738:0.007312:0.013143:0.003848:0.012604:0.011738:0.012508:0.005330:0.012427:0.007312:0.014239:0.003848:0.003848:0.007312:0.012604:0.006523:0.011738:0.012508:0.005792:0.007301:0.013123:0.013143:0.006523:0.003848:0.012508:0.011738:0.006523:0.007466:0.007312:0.015990:0.003848:0.006523:0.011738:0.007312:0.017684:0.016779:0.012604:0.009583:-0.562006
19:@0.624824:0.767777:0.637254:0.767777:0.637254:0.758591:0.624824:0.758591:0.006215:0.006215
are  followed with  annual serum  and uri-:@0.523632:0.789681:0.914570:0.789681:0.914570:0.773925:0.523632:0.773925:0.013143:0.005715:0.012508:0.005330:0.003704:0.006042:0.012604:0.003848:0.003848:0.012604:0.015990:0.012508:0.013181:0.009044:0.015990:0.003848:0.006523:0.011738:0.005330:0.003704:0.013143:0.011738:0.011738:0.011699:0.013143:0.003848:0.009044:0.007466:0.012508:0.005792:0.011699:0.018049:0.005330:0.003704:0.013143:0.011738:0.013181:0.009044:0.011699:0.005792:0.003848:0.006388
nary M-protein, FBC, creatinine and serum :@0.523632:0.805966:0.919875:0.805966:0.919875:0.790210:0.523632:0.790210:0.011738:0.013143:0.005792:0.010314:0.005105:0.017684:0.006388:0.013123:0.005715:0.012604:0.006523:0.012508:0.003848:0.011738:0.005330:0.005097:0.009333:0.011045:0.015644:0.005330:0.005107:0.012450:0.005711:0.012508:0.013143:0.006523:0.003848:0.011738:0.003848:0.011738:0.012508:0.005105:0.013143:0.011738:0.013181:0.005109:0.007466:0.012508:0.005792:0.011699:0.018049:0.005330
calcium. Features considered “red flags” :@0.523632:0.822251:0.919881:0.822251:0.919881:0.806495:0.523632:0.806495:0.012450:0.013143:0.003848:0.012450:0.003848:0.011699:0.018049:0.005330:0.008190:0.009333:0.012508:0.013143:0.006523:0.011699:0.005711:0.012508:0.007466:0.008190:0.012450:0.012604:0.011738:0.007466:0.003848:0.013181:0.012508:0.005711:0.012508:0.013181:0.008188:0.009660:0.005711:0.012508:0.013181:0.008186:0.004666:0.004666:0.013143:0.012950:0.007466:0.009313:0.005330
in these patients are bone pain, fatigue, :@0.523632:0.838536:0.919900:0.838536:0.919900:0.822780:0.523632:0.822780:0.003848:0.011738:0.008197:0.006523:0.011738:0.012508:0.007466:0.012508:0.008197:0.013123:0.013143:0.006523:0.003848:0.012508:0.011738:0.006523:0.007466:0.008197:0.013143:0.005715:0.012508:0.008197:0.013123:0.012604:0.011738:0.012508:0.008188:0.013123:0.013143:0.003848:0.011738:0.005330:0.008197:0.006042:0.013143:0.006523:0.003848:0.012950:0.011699:0.012508:0.005330:0.005330
constitutional symptoms, bleeding, lym-:@0.523632:0.854821:0.914522:0.854821:0.914522:0.839065:0.523632:0.839065:0.012450:0.012604:0.011738:0.007466:0.006523:0.003848:0.006523:0.011699:0.006523:0.003848:0.012604:0.011738:0.013143:0.003848:0.013258:0.007466:0.010314:0.018049:0.013123:0.006523:0.012604:0.018049:0.007466:0.005330:0.013258:0.013123:0.003848:0.012508:0.012508:0.013181:0.003848:0.011738:0.012950:0.005330:0.013258:0.003848:0.010314:0.018049:0.006388
phadenopathy or splenomegaly.:@0.523632:0.871106:0.832992:0.871106:0.832992:0.855351:0.523632:0.855351:0.013123:0.011738:0.013143:0.013181:0.012508:0.011738:0.012604:0.013123:0.013143:0.006523:0.011738:0.010314:0.005330:0.012604:0.005792:0.005330:0.007466:0.013123:0.003848:0.012508:0.011738:0.012604:0.018049:0.012508:0.012950:0.013143:0.003848:0.010314:0.005330
Patients  with SMM and plasmacytoma :@0.541816:0.887392:0.919893:0.887392:0.919893:0.871636:0.541816:0.871636:0.011392:0.013143:0.006523:0.003848:0.012508:0.011738:0.006523:0.007466:0.005330:0.003820:0.015990:0.003848:0.006523:0.011738:0.009159:0.009583:0.017684:0.017684:0.009159:0.013143:0.011738:0.013181:0.009159:0.013123:0.003848:0.013143:0.007466:0.018061:0.013143:0.012450:0.010314:0.006523:0.012604:0.018049:0.013143:0.005330
require a thorough investigation to ex-:@0.523632:0.903677:0.914545:0.903677:0.914545:0.887921:0.523632:0.887921:0.005713:0.012508:0.013123:0.011699:0.003848:0.005715:0.012508:0.012488:0.013143:0.012488:0.006523:0.011738:0.012604:0.005702:0.012604:0.011699:0.012950:0.011738:0.012488:0.003848:0.011738:0.010660:0.012508:0.007466:0.006523:0.003848:0.012950:0.013143:0.006523:0.003848:0.012604:0.011738:0.012488:0.006523:0.012604:0.012488:0.012508:0.009236:0.006388
clude MM, including cross-sectional imag-:@0.523632:0.919962:0.914537:0.919962:0.914537:0.904206:0.523632:0.904206:0.012450:0.003848:0.011699:0.013181:0.012508:0.005157:0.017684:0.017684:0.005330:0.005157:0.003848:0.011738:0.012450:0.003848:0.011699:0.013181:0.003848:0.011738:0.012950:0.005157:0.012450:0.005711:0.012604:0.007466:0.007466:0.006388:0.007466:0.012508:0.012450:0.006523:0.003848:0.012604:0.011738:0.013143:0.003848:0.005157:0.003848:0.018049:0.013143:0.012950:0.006388
ing studies and FLC assay. These patients :@0.523632:0.936247:0.919887:0.936247:0.919887:0.920491:0.523632:0.920491:0.003848:0.011738:0.012950:0.007264:0.007466:0.006523:0.011699:0.013181:0.003848:0.012508:0.007466:0.007274:0.013143:0.011738:0.013181:0.007274:0.009333:0.008890:0.015644:0.007260:0.013143:0.007466:0.007466:0.013143:0.010314:0.005330:0.007274:0.008197:0.011738:0.012508:0.007466:0.012508:0.007274:0.013123:0.013143:0.006523:0.003848:0.012508:0.011738:0.006523:0.007466:0.005330